Hodgkin's disease and the risk of acute leukemia in successfully treated patients.
Valagussa
P
P
Bonadonna
G
G
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use; D001761:Bleomycin / Q000008:administration & dosage / Q000009:adverse effects; D003131:Combined Modality Therapy; D003606:Dacarbazine / Q000008:administration & dosage / Q000009:adverse effects; D004198:Disease Susceptibility; D004317:Doxorubicin / Q000008:administration & dosage / Q000009:adverse effects; D005500:Follow-Up Studies; D006689:Hodgkin Disease / Q000150:complications / Q000628:therapy*; D006801:Humans; D007558:Italy / Q000453:epidemiology; D015470:Leukemia, Myeloid, Acute / Q000139:chemically induced / Q000453:epidemiology* / Q000209:etiology; D007953:Leukemia, Radiation-Induced / Q000453:epidemiology / Q000209:etiology; D008466:Mechlorethamine / Q000008:administration & dosage / Q000009:adverse effects; D016609:Neoplasms, Second Primary / Q000139:chemically induced / Q000453:epidemiology* / Q000209:etiology; D011241:Prednisone / Q000008:administration & dosage / Q000009:adverse effects; D011344:Procarbazine / Q000008:administration & dosage / Q000009:adverse effects; D012306:Risk; D013156:Splenectomy / Q000009:adverse effects; D014747:Vinblastine / Q000008:administration & dosage / Q000009:adverse effects; D014750:Vincristine / Q000008:administration & dosage / Q000009:adverse effects; D014916:Whole-Body Irradiation / Q000009:adverse effects
D001761:Bleomycin; D011344:Procarbazine; D008466:Mechlorethamine; D014750:Vincristine; D014747:Vinblastine; D003606:Dacarbazine; D004317:Doxorubicin; D011241:Prednisone